BioNexus Gene Lab Corp Common stock (BGLC)
Company Info
Sector | Basic Materials |
---|---|
Industry | Specialty Chemicals |
Highlights
Market Cap | $10.49M |
---|---|
EPS | -$0.18 |
Revenue (TTM) | $9.77M |
Gross Profit (TTM) | $2.19M |
EBITDA (TTM) | -$1.96M |
Year Range | $0.31 - $17.52 |
Short % | 0.58% |
Short Ratio | 1.15 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in BioNexus Gene Lab Corp Common stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
BioNexus Gene Lab Corp Common stock had a return of 15.85% year-to-date (YTD) and -84.39% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | 15.85% | 5.21% |
1 month | -2.54% | -4.30% |
6 months | 65.95% | 18.42% |
1 year | -84.39% | 21.82% |
5 years (annualized) | N/A | 11.27% |
10 years (annualized) | N/A | 10.33% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | -11.51% | 21.32% | 24.08% | -12.18% | ||||||||
2023 | -51.84% | 126.73% | -44.21% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of BGLC is 46, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
BioNexus Gene Lab Corp Common stock(BGLC)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for BioNexus Gene Lab Corp Common stock (BGLC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the BioNexus Gene Lab Corp Common stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioNexus Gene Lab Corp Common stock was 99.00%, occurring on Nov 10, 2023. The portfolio has not yet recovered.
The current BioNexus Gene Lab Corp Common stock drawdown is 98.14%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-99% | Nov 3, 2020 | 463 | Nov 10, 2023 | — | — | — |
-60% | Sep 18, 2020 | 1 | Sep 18, 2020 | 11 | Oct 26, 2020 | 12 |
-23.27% | Oct 27, 2020 | 2 | Oct 28, 2020 | 2 | Nov 2, 2020 | 4 |
Volatility
Volatility Chart
The current BioNexus Gene Lab Corp Common stock volatility is 48.57%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |